Eseroline: Difference between revisions

Jump to navigation Jump to search
m (Protected "Eseroline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
(One intermediate revision by the same user not shown)
Line 27: Line 27:
| routes_of_administration =  
| routes_of_administration =  
}}
}}
{{EH}}
 


==Overview==
==Overview==
Line 36: Line 36:


== References ==
== References ==
<references />
{{reflist|2}}


{{opioids}}
{{opioids}}

Latest revision as of 17:11, 4 September 2012

Eseroline
Clinical data
SynonymsEseroline
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC13H18N2O
Molar mass218.295 g/mol
3D model (JSmol)


Overview

Eseroline is a drug which acts as an opioid agonist.[1] It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible,[2][3] and it produces fairly potent analgesic effects mediated through the μ-opioid receptor.[4] This mixture of activities gives eseroline an unusual pharmacological profile,[5][6] although its uses are limited by side effects such as respiratory depression[7] and neurotoxicity.[8]



References

  1. Fürst S, Friedmann T, Bartolini A, Bartolini R, Aiello-Malmberg P, Galli A, Somogyi GT, Knoll J. Direct evidence that eseroline possesses morphine-like effects. European Journal of Pharmacology. 1982 Sep 24;83(3-4):233-41. PMID 6293841
  2. Jhamandas K, Elliott J, Sutak M. Opiatelike actions of eseroline, an eserine derivative. Canadian Journal of Physiology and Pharmacology. 1981 Mar;59(3):307-10. PMID 7194726
  3. Galli A, Renzi G, Grazzini E, Bartolini R, Aiello-Malmberg P, Bartolini A. Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine. Biochemical Pharmacology. 1982 Apr 1;31(7):1233-8. PMID 7092918
  4. Agresti A, Buffoni F, Kaufman JJ, Petrongolo C. Structure-activity relationships of eseroline and morphine: ab initio quantum-chemical study of the electrostatic potential and of the interaction energy with water. Molecular Pharmacology. 1980 Nov;18(3):461-7. PMID 7464812
  5. Galli A, Ranaudo E, Giannini L, Costagli C. Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences. Journal of Pharmacy and Pharmacology. 1996 Nov;48(11):1164-8. PMID 8961166
  6. Liu WF. Effect of eseroline on schedule-controlled behavior in the rat. Pharmacology, Biochemistry and Behaviour. 1991 Apr;38(4):747-51. PMID 1871191
  7. Berkenbosch A, Rupreht J, DeGoede J, Olievier CN, Wolsink JG. Effects of eseroline on the ventilatory response to CO2. European Journal of Pharmacology. 1993 Feb 23;232(1):21-8. PMID 8458393
  8. Somani SM, Kutty RK, Krishna G. Eseroline, a metabolite of physostigmine, induces neuronal cell death. Toxicology and Applied Pharmacology. 1990 Oct;106(1):28-37. PMID 2251681

Template:Opioids Template:WH Template:WS